Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
Are there specific types of bioprosthetic valves that would make you inclined to choose VKA in lieu of a DOAC for systemic anticoagulation several months post-valve replacement?
Related Questions
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
What would be your approach for the management of asymptomatic, severe AS with a peak velocity of 5 m/s in an otherwise physically active patient in their mid-90s without significant co-morbidities?
Are there instances where TAVR should be considered for patients with moderate AS and HFrEF?
How would you approach the INR goal in a patient with mechanical aortic valve and high bleeding risk factors like immune thrombocytopenia, AV malformations and recurrent GI bleeds, etc.?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
How should one approach management of a patient with asymptomatic severe primary (prolapse) TR and normal RV function (EF and strain) but with RA/RV enlargement?
Would you recommend starting an SGLT-2 inhibitors in patients with non-severe aortic stenosis based on recent evidence suggesting it may slow progression of disease?
How do you decide the duration of DAPT following TAVR, especially for patients already on a DOAC?
Are there any indications for valve intervention in asymptomatic patients with moderate AS?
In a patient with severe TR, when is the best time to start thinking about T-TEER?
